1 / 19

Use of p63 in assessing mimics of prostatic adenocarcinoma

Use of p63 in assessing mimics of prostatic adenocarcinoma. DR. A. T. ATANDA, BAYERO UNIVERSITY/AMINU KANO TEACHING HOSP. KANO. BACKGROUND.

colorado-butler
Download Presentation

Use of p63 in assessing mimics of prostatic adenocarcinoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Use of p63 in assessing mimics of prostatic adenocarcinoma DR. A. T. ATANDA, BAYERO UNIVERSITY/AMINU KANO TEACHING HOSP. KANO

  2. BACKGROUND • Prostatic carcinoma has several well documented mimics, particularly on core needle biopsy, for which the pathologist cannot rely on morphology alone for their differential diagnosis. • Correct evaluation of these mimics will help prevent unnecessary treatment for cancer.

  3. Mimics of Prostatic Carcinoma • Atrophy • Basal Cell Hyperplasia • Adenosis • Seminal vesicles • Ganglia • Paraganglia

  4. AIM • To evaluate the reliability of morphology alone measured against immunohistochemistry in evaluating equivocal prostatic biopsies.

  5. METHODOLOGY • p63 immunohistochemical stain (clone BC4A4) • equivocal impressions of benign versus malignant diagnoses over a • 12-month period(Jan – Dec., 2013) • Negative stain = positive for malignancy • Positive stain = negative for malignancy

  6. Criteria for diagnosis of CaP Major criteria • infiltrative acini which may have cribriform disposition • absence of basal cells; and • nuclear and/or nucleolar enlargement. Minor criteria included: adjacent high grade PIN and nuclear hyperchromasia • others • mucinous fibroplasia, perineural invasion and glomerulations

  7. Results • 61 cases of CaP • 27(44.3%) were considered equivocal. • 6 (22.2%) of the 27 showed basal cell staining • 3 cases of atrophy • basal cell hyperplasia • clear cell cribriform hyperplasia • Urothelium

  8. Results • The probability of erroneous interpretation ranged btw 8.7% and42.3% • PPV of morphology alone was 77.8%.

  9. RESULT ctd • Sensitivity of 100% (83.8% to 100%); • Specificity of 77.8% (57.7% to 91.3%); • NPV of 100%.

  10. Discussion • Our study • 22.2% reclassified; Error rate 8.7% (sensitivity:77.8%; specificity: 100%) • 7.5% error rate reported by Berneyet at1 (London) • 1.3% documented by Epstein et al2in the US • 100% and 64%.3

  11. Reasons for lower specificity by morphology • Surgeons • Sample adequacy (volume & number) • Crush artifacts • Cauterization artifacts • Pathologists • Good sections • inexperience

  12. Discussion • The use of immunohistochemical staining for p63 protein alone, or as a component of a cocktail comprising p63, alpha-methyl-CoA-racemase (AMACR) and Cytokeratin CK903,3is also gaining momentum.

  13. conclusion • For improvement in diagnosis of carcinoma of prostate, particularly from core needle biopsies, there is need for pathologists to pay attention to the common mimics of carcinoma and incorporate immunohistochemistry into their diagnostic armamentarium.

  14. References • Berney DM, Fisher G, Kattan MW, Oliver RT, Møller H, Fearn P, et al; Trans-Atlantic prostate group.Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome.Histopathology 2007; 51: 452-7. • Epstein JI, Walsh PC, Sanfilippo F. Clinical and cost impact of second-opinion pathology: review of prostate biopsies prior to radical prostatectomy. Am J SurgPathol 1996; 20: 851-7. • Tokumaru Y, Harden S V, Sun D I, Yamashita K, Epstein J I, Sidransky D. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 2004; 10: 5518-22. • z

More Related